Affinity Asset Advisors’s Travere Therapeutics TVTX Stock Holding History

Affinity Asset Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17M	Hold	300,000	–	–	0.77%	39
2026 Q1	$8.91M	Hold	300,000	–	–	0.46%	55
2025 Q4	$11.5M	Sell	300,000 -200,000	-40%	-$6.5M	0.65%	42
2025 Q3	$11.9M	Sell	500,000 -470,000	-48%	-$8.84M	1.04%	32
2025 Q2	$14.4M	Sell	970,000 -100,000	-9%	-$1.66M	1.96%	14
2025 Q1	$19.2M	Buy	1,070,000 +870,000	+435%	+$17.7M	1.83%	15
2024 Q4	$3.48M	Buy	+200,000	New	+$3.54M	0.47%	44
2024 Q2	–	Sell	-125,000	Closed	-$964K	–	122
2024 Q1	$964K	Buy	+125,000	New	+$1.05M	0.12%	83
2023 Q4	–	Sell	-100,000	Closed	-$894K	–	98
2023 Q3	$894K	Buy	+100,000	New	+$1.41M	0.25%	64
2022 Q2	–	Sell	-100,000	Closed	-$2.58M	–	69
2022 Q1	$2.58M	Buy	100,000 +50,000	+100%	+$1.33M	0.41%	33
2021 Q4	$1.55M	Sell	50,000 -150,000	-75%	-$4.22M	0.56%	41
2021 Q3	$4.85M	Buy	+200,000	New	+$3.67M	1.22%	20
2021 Q2	–	Sell	-220,000	Closed	-$5.49M	–	78
2021 Q1	$5.49M	Buy	+220,000	New	+$6.08M	1.87%	13

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Asset Advisors's TVTX Position: Q2 2026 in Review

Affinity Asset Advisors held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 300,000 shares worth $17M. The position accounts for 0.77% of the portfolio, ranked #39.

Affinity Asset Advisors first reported a position in TVTX in Q1 2021 and has held it in 13 quarters since. The position peaked at $19.2M in Q1 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Affinity Asset Advisors held 300,000 shares of Travere Therapeutics worth $17M as of Q2 2026.
Affinity Asset Advisors left its Travere Therapeutics share count unchanged in Q2 2026.
Travere Therapeutics made up 0.77% of Affinity Asset Advisors's portfolio in Q2 2026, its #39 holding.
Affinity Asset Advisors first reported a position in Travere Therapeutics in Q1 2021 and has held it in 13 quarters since.
Affinity Asset Advisors's Travere Therapeutics position peaked at $19.2M in Q1 2025.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.